Balchem Corp (BCPC) · Oct 23, 2026 · Earnings

Balchem earnings in line as all three segments post growth

In line — Adjusted EPS $1.57 vs ~$1.57 consensus; sales $290.7M vs ~$289–295M

Balchem’s Q3 earnings were broadly in line with expectations, with sales growth across all three segments, wider margins, and stronger cash flow.

Balchem is a specialty-ingredients company building around human nutrition, animal nutrition, and specialty products such as performance gases and plant nutrients. Its current growth story is led by differentiated nutrition technologies and a broad innovation pipeline across those markets.

The quarter was essentially on the market’s numbers, not a surprise beat. Published estimates clustered around roughly $289–295 million of revenue and $1.57 of adjusted EPS; Balchem delivered $290.7 million and $1.57, respectively.

MetricQ3 2026Q3 2025Change / comparison
Net sales$290.7M$267.6M+8.6%
GAAP diluted EPS$1.46$1.24+17.7%
Adjusted diluted EPS$1.57$1.35+16.3%; in line with consensus
Adjusted EBITDA$80.3M$71.4M+12.4%
Free cash flow$57.9M$50.7M+14.3%
Gross margin36.4%35.7%+70 bps

The underlying business remained broad-based rather than dependent on one segment. Human Nutrition and Health, the largest division, grew sales 8.1% and operating earnings 11.8%, while Animal Nutrition and Health grew sales 11.7% and operating earnings 82.8%. Specialty Products also grew sales 4.5% and operating earnings 6.6%.

Profit conversion was better than the sales growth. Gross margin expanded 70 basis points to 36.4%, helped by favorable mix and manufacturing efficiencies, while adjusted EBITDA rose 12.4%—ahead of the 8.6% sales increase. That makes this more than a volume-only quarter, although the company still cited higher manufacturing input costs as a partial offset.

Cash generation and balance-sheet execution continued to support the growth plan. Nine-month operating cash flow reached $156.5 million, free cash flow was $128.0 million, and revolving debt fell to $124.0 million from $164.0 million at year-end. The company also repurchased about $28 million of stock during the quarter.

There was no new full-year guidance or strategic reset in this filing. Management reiterated confidence in the long-term growth outlook and highlighted upcoming product innovation, so the release strengthens the existing execution story rather than materially changing it.

Bottom line: This was a solid, broad-based quarter that met expectations rather than exceeded them. The business is executing cleanly—with improving margins, cash flow, and leverage—but the filing adds confirmation more than surprise.

What to watch next

SupplySide Global product showcase

Original filing on SEC EDGAR

Balchem earnings in line as all three segments post growth | BCPC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.